Where is CTMC located?

CTMC is headquartered in Houston, United States.

How many employees does CTMC have?

As of Apr 30, 2026, the latest employee count at CTMC is 130.

Is CTMC a funded company?

CTMC is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does CTMC rank among its competitors?

CTMC ranks 32nd amongst 131 active competitors, of which 27 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was XDemics, which secured $7.4M in Oct, 2025.

Who are the top competitors of CTMC?

CTMC's top competitors include Blue Rock Therapeutics, CellCarta and Invivyd. Among them, XDemics secured the most recent funding round in October, 2025.

CTMC - 2026 Company Profile & Competitors

CTMC's employee count trend

CTMC has 130 employees as of Apr 26. Here is CTMC's employee count trend over the years:

Uncover CTMC's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CTMC include Blue Rock Therapeutics, CellCarta and Invivyd. Here is the list of Top 10 competitors of CTMC, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
2nd	CellCarta 2002, Montreal (Canada), Acquired	CRO focused on providing histopathology and genomics services	$7.5M	Waters Corporation, Great Point Partners & 5 others	59/100
3rd	Invivyd 2022, Waltham (United States), Public	Provider of drug research & development targets stem cell and clinical trial services	-	Orbimed, Premji Invest & 1 others	53/100
4th	Kincell Bio 2023, Gainesville (United States), Series A	Provider of clinical cell therapy development & manufacturing and consulting services	$58M	NewSpring, Kineticos	49/100
5th	BioBridge Global 1974, San Antonio (United States), Unfunded	Manufacturer of cell and gene therapy clinical product & testing services	-	-	45/100
6th	GC Green Cross Lab Cell 2008, Yongin si (South Korea), Funding Raised	Provider of research, development, and manufacturing services for cell & gene therapy products	-	-	44/100
7th	XDemics 2017, Monrovia (United States), Series B	CDMO focused on manufacturing cell & viral based therapeutics	$14.8M	-	42/100
8th	Impel Pharmaceuticals 2008, Seattle (United States), Acquired	Provider of trans-formative therapy development and commercialisation services	$67.5M	Norwest, KKR & 4 others	41/100
9th	VintaBio 2020, Philadelphia (United States), Series C	Life sciences company specializing in alleviating the viral vector bottleneck in cell and gene therapy development	$64M	Decheng Capital	28/100
10th	Shanghai Cell Therapy Group 2014, Shanghai (China), Series D	Provider of cell-therapy focused research and development services	$202M	CCB International, Jiuzhou Venture Capital ... & 7 others	38/100
32nd	CTMC 2022, Houston (United States), Unfunded	Provider of drug research & development and clinical trial services for cell & gene therapeutic services	-	-	25/100